Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | USP14 | P54578 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536327 | 0.89 | DGAT1 (0.37) | KDM4EALDH1A1SYKLCKJAK3 | |
| SCHEMBL5533315 | 0.84 | KDM4D (0.36) | JAK3ACACBBTK | |
| SCHEMBL5532095 | 0.80 | KDM4E (0.58) | KDM4EALDH1A1MAPTLCKJAK3 | |
| SCHEMBL5538159 | 0.80 | KDM4E (0.58) | KDM4EALDH1A1MAPTLCKJAK3 | |
| SCHEMBL5535313 | 0.79 | DGAT1 (0.35) | KDM4EALDH1A1KDM1AHPGDACACB | |
| SCHEMBL8409543 | 0.76 | KDM1A (0.41) | KDM1AUSP14 | |
| SCHEMBL5538227 | 0.74 | MAPT (0.52) | KDM4EALDH1A1MAPTLCKJAK3 | |
| SCHEMBL5538202 | 0.73 | DGAT1 (0.62) | SYK | |
| SCHEMBL5535294 | 0.73 | ALDH1A1 (0.38) | KDM4EALDH1A1MAPTLCKJAK3 | |
| SCHEMBL5533302 | 0.72 | CETP (0.41) | KDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | KDM4E 2106/4885ALDH1A1 277/4885MAPT 3037/4885 |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | KDM4E 2125/4885ALDH1A1 272/4885MAPT 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.